Scynexis (SCYX) Asset Writedowns and Impairment (2015 - 2016)

Scynexis' (SCYX) quarterly Asset Writedowns and Impairment came in at $111000.0 in Q1 2016, down 91.78% on a QoQ basis from $1.3 million in Q2 2015.

Scynexis (SCYX) Asset Writedowns and Impairment (2015 - 2016) Analysis & Trends

Scynexis (SCYX) has 2 years of Asset Writedowns and Impairment data on file, last reported at $111000.0 in Q1 2016.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $111000.0 in Q1 2016, while the trailing twelve-month figure through Dec 2016 was $111000.0 (down 91.78% YoY) and the FY2023 annual result came in at $14.6 million, changed N/A from the prior year.
Asset Writedowns and Impairment slipped to $111000.0 in Q1 2016, from $1.3 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.3 million in Q2 2015 to a low of $111000.0 in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Scynexis	61.37 Mn	-53.33 Mn	-

Download Data